Loading clinical trials...

Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide | Clinical Trials | Clareo Health

TERMINATED

Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide

Ovarian Aging in Women Newly Diagnosed With Low Grade Glioma Treated With Temozolomide (Temodar®)

NCT01452854•University of California, San Francisco

Summary

The purpose of this study is to look at how a chemotherapy treatment (Temozolomide, also called Temodar) affects the process of ovarian aging which is measured by a decline in ovarian follicle count, in patients with Low Grade Glioma (LGG). It is important to know if different patient factors and Temozolomide influence the rate of ovarian aging in women with LGG who have good long-term survival rates. This will allow better counseling about the effects of this particular chemotherapy agent on fertility in women.

Detailed Description

Understanding how Temozolomide influences ovarian aging would be important information for physicians to predict the possibility of infertility (the inability to become pregnant) following recovery from Temozolomide treatment. Physicians would like to provide better individualized recommendations for cancer patients regarding timing of planned treatment and future pregnancy. We will do this by comparing data from the women being treated for Low Grade Glioma with Temozolomide to a similar group of women who have been unaffected by cancer or cancer treatment.

Eligibility

Age

18 - 44 years

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Premenopausal women ages 18-44 newly diagnosed with LGG
•Patients with histologically proven supratentorial low grade glioma.
•Patients may or may not have had a surgical resection.
•Patients must be expected to live the length of study
•Patients must be able to provide informed consent according to institutional guidelines.

Exclusion Criteria

•Prior ovarian resection, unilateral or bilateral oophorectomy, hysterectomy or radiation to pelvic region.
•Pregnancy or breast feeding.
•Diagnosis of another malignancy, unless the patient was diagnosed at least 2 years earlier and has been disease-free for at least 6 months following the completion of curative intent therapy with the following exceptions: Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed.
•Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.
•Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).
•Patient is, at the time of signing informed consent, a regular user (including "recreational use") of any illicit drugs, substance abuse or had a recent history (within the last year) of drug or alcohol abuse
•Patient has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study or is not in the best interest of the patient.

Locations (1)

UCSF Center for Reproductive Health

San Francisco, California, United States

Key Dates

Start Date

October 1, 2011

Primary Completion Date

November 1, 2013

Completion Date

November 1, 2013

Last Updated

July 8, 2022

Enrollment

ACTUAL participants

Conditions

Low Grade Glioma

A Study to Test a New Fluid to Improve the Quality of Images Obtained by Using Sound Waves (Ultrasound) During Surgery

NCT07042620

Brain Tumor AdultLow Grade Glioma (LGG), High Grade Glioma (HGG)+1 more

View study

RECRUITINGPHASE2

Feasibility of Individualized, Model-guided Optimization of Proton Beam Treatment Planning in Patients With Low Grade Glioma

NCT05964569

Low Grade Glioma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 8, 2022Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide

Inclusion Criteria

Exclusion Criteria

A Study to Test a New Fluid to Improve the Quality of Images Obtained by Using Sound Waves (Ultrasound) During Surgery

Feasibility of Individualized, Model-guided Optimization of Proton Beam Treatment Planning in Patients With Low Grade Glioma

A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Proton Radiation Therapy for Gliomas

Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma